Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aehr Test Systems stock logo
AEHR
Aehr Test Systems
$26.29
+7.2%
$18.57
$6.27
$27.51
$733.52M2.541.93 million shs1.38 million shs
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$11.88
-1.0%
$10.63
$3.91
$13.98
$827.13M1.93618,499 shs742,789 shs
Transcat, Inc. stock logo
TRNS
Transcat
$77.65
-3.1%
$83.14
$67.56
$133.72
$746.65M0.72102,000 shs135,055 shs
10x Genomics stock logo
TXG
10x Genomics
$13.57
+1.7%
$13.10
$6.78
$24.38
$1.66B22.84 million shs1.71 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aehr Test Systems stock logo
AEHR
Aehr Test Systems
+7.22%-2.81%+42.26%+131.83%+100.53%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
-1.00%+2.41%+9.09%+32.89%+42.11%
Transcat, Inc. stock logo
TRNS
Transcat
-3.08%-8.10%+2.66%-0.42%-36.98%
10x Genomics stock logo
TXG
10x Genomics
+1.72%-4.97%+1.95%+44.06%-40.66%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aehr Test Systems stock logo
AEHR
Aehr Test Systems
$26.29
+7.2%
$18.57
$6.27
$27.51
$733.52M2.541.93 million shs1.38 million shs
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$11.88
-1.0%
$10.63
$3.91
$13.98
$827.13M1.93618,499 shs742,789 shs
Transcat, Inc. stock logo
TRNS
Transcat
$77.65
-3.1%
$83.14
$67.56
$133.72
$746.65M0.72102,000 shs135,055 shs
10x Genomics stock logo
TXG
10x Genomics
$13.57
+1.7%
$13.10
$6.78
$24.38
$1.66B22.84 million shs1.71 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aehr Test Systems stock logo
AEHR
Aehr Test Systems
+7.22%-2.81%+42.26%+131.83%+100.53%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
-1.00%+2.41%+9.09%+32.89%+42.11%
Transcat, Inc. stock logo
TRNS
Transcat
-3.08%-8.10%+2.66%-0.42%-36.98%
10x Genomics stock logo
TXG
10x Genomics
+1.72%-4.97%+1.95%+44.06%-40.66%
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aehr Test Systems stock logo
AEHR
Aehr Test Systems
$58.97M13.34$0.12 per share228.05$4.13 per share6.37
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$43.27M18.93N/AN/A$4.93 per share2.41
Transcat, Inc. stock logo
TRNS
Transcat
$278.42M2.60$4.14 per share18.77$30.82 per share2.52
10x Genomics stock logo
TXG
10x Genomics
$610.78M2.77N/AN/A$5.81 per share2.34
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aehr Test Systems stock logo
AEHR
Aehr Test Systems
-$3.91M-$0.13N/A119.50N/A-6.63%-0.15%-0.13%10/9/2025 (Estimated)
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
-$130.87M-$2.68N/AN/AN/A-337.93%-63.80%-50.72%11/6/2025 (Estimated)
Transcat, Inc. stock logo
TRNS
Transcat
$14.52M$1.4354.3029.52N/A4.64%6.66%5.09%10/27/2025 (Estimated)
10x Genomics stock logo
TXG
10x Genomics
-$182.63M-$0.70N/AN/AN/A-13.13%-12.88%-10.03%10/27/2025 (Estimated)

Latest AEHR, TXG, EYPT, and TRNS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
10x Genomics stock logo
TXG
10x Genomics
-$0.35$0.28+$0.63$0.28$139.36 million$172.91 million
8/6/2025Q2 2025
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
-$0.67-$0.85-$0.18-$0.85$6.82 million$5.33 million
8/6/2025Q1 2026
Transcat, Inc. stock logo
TRNS
Transcat
$0.40$0.59+$0.19$0.35$72.28 million$76.42 million
7/8/2025Q4 2025
Aehr Test Systems stock logo
AEHR
Aehr Test Systems
-$0.02-$0.01+$0.01-$0.10$14.83 million$14.10 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aehr Test Systems stock logo
AEHR
Aehr Test Systems
N/AN/AN/AN/AN/A
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
N/AN/AN/AN/AN/A
Transcat, Inc. stock logo
TRNS
Transcat
N/AN/AN/AN/AN/A
10x Genomics stock logo
TXG
10x Genomics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aehr Test Systems stock logo
AEHR
Aehr Test Systems
N/A
5.68
2.99
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
N/A
8.00
7.91
Transcat, Inc. stock logo
TRNS
Transcat
0.11
2.92
2.36
10x Genomics stock logo
TXG
10x Genomics
N/A
5.84
5.23

Institutional Ownership

CompanyInstitutional Ownership
Aehr Test Systems stock logo
AEHR
Aehr Test Systems
69.69%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
99.41%
Transcat, Inc. stock logo
TRNS
Transcat
98.34%
10x Genomics stock logo
TXG
10x Genomics
84.68%

Insider Ownership

CompanyInsider Ownership
Aehr Test Systems stock logo
AEHR
Aehr Test Systems
6.20%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
4.46%
Transcat, Inc. stock logo
TRNS
Transcat
2.80%
10x Genomics stock logo
TXG
10x Genomics
9.39%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aehr Test Systems stock logo
AEHR
Aehr Test Systems
9029.92 million28.06 millionOptionable
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
12068.93 million65.85 millionOptionable
Transcat, Inc. stock logo
TRNS
Transcat
1,2459.32 million9.06 millionOptionable
10x Genomics stock logo
TXG
10x Genomics
1,240124.49 million112.80 millionOptionable

Recent News About These Companies

RA Capital Management L.P. Trims Stake in 10x Genomics $TXG
10x Genomics $TXG Shares Purchased by PDT Partners LLC
Omnicell (NASDAQ:OMCL) vs. 10x Genomics (NASDAQ:TXG) Head-To-Head Review
Ieq Capital LLC Grows Stock Position in 10x Genomics $TXG
Hsbc Holdings PLC Sells 21,746 Shares of 10x Genomics $TXG
Invesco Ltd. Purchases 73,265 Shares of 10x Genomics $TXG
Reviewing Enovis (NYSE:ENOV) & 10x Genomics (NASDAQ:TXG)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Aehr Test Systems stock logo

Aehr Test Systems NASDAQ:AEHR

$26.29 +1.77 (+7.22%)
Closing price 09/4/2025 04:00 PM Eastern
Extended Trading
$26.56 +0.27 (+1.01%)
As of 05:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aehr Test Systems provides test solutions for testing, burning-in, and semiconductor devices in wafer level, singulated die, and package part form, and installed systems worldwide. Its product portfolio includes FOX-XP and FOX-NP systems that are full wafer contact and singulated die/module test and burn-in systems that can test, burn-in, and stabilize range of devices, including silicon carbide-based and other power semiconductors, 2D and 3D sensors used in mobile phones, tablets and other computing devices, memory semiconductors, processors, microcontrollers, systems-on-a-chip, and photonics and integrated optical devices. The company also offers FOX-CP system, a low-cost single-wafer compact test solution for logic, memory, and photonic devices; FOX WaferPak Contactor, a full wafer contactor capable of testing wafers up to 300mm that enables integrated circuit manufacturers to perform test, burn-in, and stabilization of full wafers on the FOX-P systems. In addition, it provides FOX DiePak Carrier, a reusable temporary package that enables IC manufacturers to perform final test and burn-in of bare die and modules; and FOX DiePak Loader. The company was incorporated in 1977 and is headquartered in Fremont, California.

Eyepoint Pharmaceuticals stock logo

Eyepoint Pharmaceuticals NASDAQ:EYPT

$11.88 -0.12 (-1.00%)
Closing price 09/4/2025 04:00 PM Eastern
Extended Trading
$12.00 +0.11 (+0.97%)
As of 04:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Transcat stock logo

Transcat NASDAQ:TRNS

$77.65 -2.47 (-3.08%)
Closing price 09/4/2025 04:00 PM Eastern
Extended Trading
$77.66 +0.00 (+0.01%)
As of 09/4/2025 06:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Transcat, Inc. provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services. This segment also provides CalTrak, a proprietary document and asset management system that is used to manage the workflow of its calibration service centers and customers' assets; and Compliance, Control and Cost, an online customer portal that provides its customers with web-based asset management capability, as well as a safe and secure off-site archive of calibration and other service records. The Distribution segment sells and rents test, measurement, and control instruments for customers' test and measurement instrumentation needs, as well as value added services, such as calibration/certification of equipment purchase, equipment rental, used equipment for sale, and equipment kitting. This segment markets and sells its products through website, digital and print advertising, proactive outbound sales, and an inbound call center. The company provides services and products to highly regulated industries, principally life science, which includes companies in the pharmaceutical, biotechnology, medical device, and other FDA-regulated industries; and additional industries, including aerospace and defense industrial manufacturing, energy and utilities, and other industries that require accuracy in processes and confirmation of the capabilities of their equipment. Transcat, Inc. was incorporated in 1964 and is headquartered in Rochester, New York.

10x Genomics stock logo

10x Genomics NASDAQ:TXG

$13.57 +0.23 (+1.72%)
Closing price 09/4/2025 04:00 PM Eastern
Extended Trading
$13.72 +0.15 (+1.14%)
As of 04:28 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.